Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ANV600 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ANV600 single agent | EXPERIMENTAL | - |
| ANV600 in combination with pembrolizumab (KEYTRUDA®) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ANV600 | DRUG | ANV600 administered by intravenous (IV) infusion |
| ANV600 + pembrolizumab (KEYTRUDA®) | DRUG | ANV600 administered by intravenous (IV) infusion pembrolizumab (KEYTRUDA®) administered by intravenous (IV) infusion |
Inclusion Criteria: * The participant provides written informed consent for the trial; * Life-expectancy ≥ 3 months; * Able to comply with the Protocol as judged by the Investigator; * ≥ 18 years of age on day of signing informed consent; * Eastern Cooperative Oncology Group (ECOG) performance stat...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ANV600 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, and the ongoing trial is evaluating ANV600 as a single agent or in combination with pembrolizumab in participants with advanced solid tumors.
ANV600 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this investigational small molecule for the treatment of advanced solid tumors.
ANV600 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial is currently active but not recruiting participants.
ANV600 is being studied in the EXPAND-1 trial, registered as NCT06470763. This Phase 1 study evaluates ANV600 as a single agent or in combination with pembrolizumab in participants with advanced solid tumors. The trial is active but not recruiting, with an enrollment of 240 participants.
Yes, ANV600 is being studied in combination with pembrolizumab in the EXPAND-1 clinical trial. The study evaluates ANV600 both as a single agent and in combination with pembrolizumab in participants with advanced solid tumors.
The ANV600 clinical trial, NCT06470763, is being conducted in multiple countries, including the United States, Belgium, France, Germany, Netherlands, Spain, and Switzerland. The trial enrolls adults aged 18 years and older with advanced solid tumors.